Cargando…

Is There a Difference in Immune Response to SARS-CoV-2 Vaccination between Liver and Lung Transplant Patients with Cystic Fibrosis?

People with Cystic Fibrosis (CF), especially solid organ transplant recipients, have been prioritized in the SARS-CoV-2 vaccination program. This study assesses antibody response of patients with CF who have undergone liver (CF-LI) or lung (CF-LU) transplantation, and compares results to published d...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuchs, Teresa, Appelt, Dorothea, Ellemunter, Helmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051295/
https://www.ncbi.nlm.nih.gov/pubmed/36992241
http://dx.doi.org/10.3390/vaccines11030657
_version_ 1785014851143204864
author Fuchs, Teresa
Appelt, Dorothea
Ellemunter, Helmut
author_facet Fuchs, Teresa
Appelt, Dorothea
Ellemunter, Helmut
author_sort Fuchs, Teresa
collection PubMed
description People with Cystic Fibrosis (CF), especially solid organ transplant recipients, have been prioritized in the SARS-CoV-2 vaccination program. This study assesses antibody response of patients with CF who have undergone liver (CF-LI) or lung (CF-LU) transplantation, and compares results to published data of patients with solid organ transplantation without CF as underlying disease. Antibodies against the spike receptor-binding domain were measured within the routine visits at the CF Centre in Innsbruck, Austria, after the second and third doses of SARS-CoV-2 mRNA vaccines. We report on 13 adult CF patients who are recipients of solid organ transplant, including five CF-LI and eight CF-LU. Overall, 69% had measurable antibody response after two, and 83% after three doses of SARS-CoV-2 vaccines. In CF-LI, positive serological response amounted to 100% after two and three doses, while CF-LU showed only a 50% and a 71% response rate, respectively. Clear differences are seen between the CF-LI and CF-LU groups in our cohort, with worse response rate for lung transplant recipients. Immune response between CF-LI and CF-LU, therefore, must be considered in a differentiated manner, and the importance of booster vaccination is once more emphasized with these data.
format Online
Article
Text
id pubmed-10051295
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100512952023-03-30 Is There a Difference in Immune Response to SARS-CoV-2 Vaccination between Liver and Lung Transplant Patients with Cystic Fibrosis? Fuchs, Teresa Appelt, Dorothea Ellemunter, Helmut Vaccines (Basel) Communication People with Cystic Fibrosis (CF), especially solid organ transplant recipients, have been prioritized in the SARS-CoV-2 vaccination program. This study assesses antibody response of patients with CF who have undergone liver (CF-LI) or lung (CF-LU) transplantation, and compares results to published data of patients with solid organ transplantation without CF as underlying disease. Antibodies against the spike receptor-binding domain were measured within the routine visits at the CF Centre in Innsbruck, Austria, after the second and third doses of SARS-CoV-2 mRNA vaccines. We report on 13 adult CF patients who are recipients of solid organ transplant, including five CF-LI and eight CF-LU. Overall, 69% had measurable antibody response after two, and 83% after three doses of SARS-CoV-2 vaccines. In CF-LI, positive serological response amounted to 100% after two and three doses, while CF-LU showed only a 50% and a 71% response rate, respectively. Clear differences are seen between the CF-LI and CF-LU groups in our cohort, with worse response rate for lung transplant recipients. Immune response between CF-LI and CF-LU, therefore, must be considered in a differentiated manner, and the importance of booster vaccination is once more emphasized with these data. MDPI 2023-03-14 /pmc/articles/PMC10051295/ /pubmed/36992241 http://dx.doi.org/10.3390/vaccines11030657 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Fuchs, Teresa
Appelt, Dorothea
Ellemunter, Helmut
Is There a Difference in Immune Response to SARS-CoV-2 Vaccination between Liver and Lung Transplant Patients with Cystic Fibrosis?
title Is There a Difference in Immune Response to SARS-CoV-2 Vaccination between Liver and Lung Transplant Patients with Cystic Fibrosis?
title_full Is There a Difference in Immune Response to SARS-CoV-2 Vaccination between Liver and Lung Transplant Patients with Cystic Fibrosis?
title_fullStr Is There a Difference in Immune Response to SARS-CoV-2 Vaccination between Liver and Lung Transplant Patients with Cystic Fibrosis?
title_full_unstemmed Is There a Difference in Immune Response to SARS-CoV-2 Vaccination between Liver and Lung Transplant Patients with Cystic Fibrosis?
title_short Is There a Difference in Immune Response to SARS-CoV-2 Vaccination between Liver and Lung Transplant Patients with Cystic Fibrosis?
title_sort is there a difference in immune response to sars-cov-2 vaccination between liver and lung transplant patients with cystic fibrosis?
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051295/
https://www.ncbi.nlm.nih.gov/pubmed/36992241
http://dx.doi.org/10.3390/vaccines11030657
work_keys_str_mv AT fuchsteresa isthereadifferenceinimmuneresponsetosarscov2vaccinationbetweenliverandlungtransplantpatientswithcysticfibrosis
AT appeltdorothea isthereadifferenceinimmuneresponsetosarscov2vaccinationbetweenliverandlungtransplantpatientswithcysticfibrosis
AT ellemunterhelmut isthereadifferenceinimmuneresponsetosarscov2vaccinationbetweenliverandlungtransplantpatientswithcysticfibrosis